www.neurologiepropraxi.cz / Neurol. praxi. 2024;25(3):216-223 / NEUROLOGIE PRO PRAXI 223 PŘEHLEDOVÉ ČLÁNKY Dravetové syndrom v dospělosti 14. Fisher JL. The anti‑convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology. 2009;56(1):190-197. doi:10.1016/j.neuro‑ pharm.2008. 06. 004. 15. Inoue Y, Ohtsuka Y, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia. 2009;50(11):2362-2368. doi:10.1111/j.1528-1167. 2009.02179.x. 16. Chiron C, Helias M, Kaminska A, et al. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood? Epilepsia. 2018;59(9):1705-1717. doi:10.1111/epi.14536. 17. Zulfiqar Ali Q, Marques P, Selvarajah A, et al. Starting sti‑ ripentol in adults with Dravet syndrome? Watch for ammo‑ nia and carnitine. Epilepsia. 2020;61(11):2435-2441. doi:10.1111/ epi.16684. 18. Martin P, Reeder T, Sourbron J, et al. An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies. Int J Mol Sci. 2021;22(16):8416. doi:10.3390/ijms22168416. 19. Guerrini R, Specchio N, Aledo‑Serrano Á, et al. An exami‑ nation of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real ‑world practice setting: A report from the Fenfluramine Eu‑ ropean Early Access Program. Epilepsia Open. 2022;7(4):578587. doi:10.1002/epi4.12624. 20. Arzimanoglou A, Brandl U, Cross JH, et al. Epilepsy and ca‑ nnabidiol: a guide to treatment. Epileptic Disord. 2020;22(1):114. doi:10.1684/epd.2020.1141. 21. Gray RA, Whalley BJ. The proposed mechanisms of ac‑ tion of CBD in epilepsy. Epileptic Disord. 2020;22(S1):10-15. doi:10.1684/epd.2020.1135. 22. Lattanzi S, Trinka E, Striano P, et al. Highly Purified Cannabi‑ diol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox‑Gastaut Syndrome. CNS Drugs. 2021;35(3):265-281. doi:10.1007/s40263021-00807-y. 23. Laux LC, Bebin EM, Checketts D, et al. Long‑term safe‑ ty and efficacy of cannabidiol in children and adults with treatment resistant Lennox‑Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Res. 2019;154:13-20. doi:10.1016/j.eplepsyres.2019. 03. 015. ODBORNÝ GARANT: doc. MUDr. Irena Doležalová, Ph.D. POŘADATEL: Společnost SOLEN, s. r. o., ve spolupráci s I. neurologickou klinikou LF MU a FN u sv. Anny ZLATÝ PARTNER Registrace ZDARMA TERMÍN květen 2024 až duben 2025 ON LINE KURZ OBSAH KURZU Co víme o syndromu Dravetové u dospělých? – prof. MUDr. Petr Marusič, Ph.D. Na co ještě myslet u dětí? – MUDr. Martin Kudr, Ph.D. Cesta k diagnóze – dialog s genetikem – MUDr. Katalin Štěrbová Cesta k diagnóze – dialog s genetikem – MUDr. Jana Zárubová Cesta k diagnóze – dialog s genetikem – MUDr. Markéta Vlčková, Ph.D. Mechanismus účinku a protizáchvatová aktivita fen uraminu – MUDr. Ondřej Horák, doc. MUDr. Irena Doležalová, Ph.D. Zaostřeno na syndrom Dravetové dostupný na online.solen.cz
RkJQdWJsaXNoZXIy NDA4Mjc=